Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of combination antiretroviral therapy (ART) for infants and children, but NNRTI resistance is increasing, leading to treatment failure. This study will test the safety, tolerability, and dosing levels of etravirine (ETR), a new NNRTI.
